Published in J Med Chem on March 25, 2010
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med (2012) 2.70
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov (2007) 1.91
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther (2008) 1.81
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) (2006) 1.63
Total synthesis of guanacastepene a: a route to enantiomeric control. J Org Chem (2005) 1.56
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
A yin-yang effect between sex chromosome complement and sex hormones on the immune response. Endocrinology (2005) 1.48
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) (2008) 1.41
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev (2007) 1.38
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther (2009) 1.35
A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther (2009) 1.31
SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res (2005) 1.29
Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.29
Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res (2008) 1.28
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Torsional steering controls the stereoselectivity of epoxidation in the guanacastepene a synthesis. Org Lett (2006) 1.18
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol Cell Neurosci (2009) 1.16
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci (2012) 1.16
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res (2006) 1.15
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol (2009) 1.13
Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A (2008) 1.12
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009) 1.12
From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology (2007) 1.12
Characterization of Gpr101 expression and G-protein coupling selectivity. Brain Res (2006) 1.11
Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des (2005) 1.08
Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide). J Pharmacol Exp Ther (2008) 1.07
The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci (2013) 1.06
Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology (2007) 1.05
Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal (2004) 1.02
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology (2007) 1.02
Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther (2006) 1.01
WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. Neuropharmacology (2008) 1.00
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther (2009) 0.99
Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci U S A (2010) 0.99
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. J Med Chem (2004) 0.98
5-HT6 medicinal chemistry. Int Rev Neurobiol (2010) 0.98
Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity. Bioorg Med Chem Lett (2010) 0.97
Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem (2005) 0.96
Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem (2010) 0.96
Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides (2007) 0.96
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther (2005) 0.96
Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists. Bioorg Med Chem (2010) 0.95
Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse. J Pharmacol Toxicol Methods (2008) 0.95
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behav Brain Res (2007) 0.94
Functional properties of alpha7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. Assay Drug Dev Technol (2008) 0.94
Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol (2004) 0.92
(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor. Bioorg Med Chem Lett (2008) 0.91
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology (Berl) (2008) 0.90
Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods to study brain neurochemistry. J Neurosci Methods (2004) 0.89
Evaluation of FLIPR Calcium 3 Assay Kit--a new no-wash fluorescence calcium indicator reagent. J Biomol Screen (2003) 0.89
Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology (Berl) (2010) 0.88
Schedule-induced polydipsia: a rat model of obsessive-compulsive disorder. Curr Protoc Neurosci (2008) 0.88
Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach. Anal Chem (2004) 0.88
Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo. Brain Res (2004) 0.87
Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett (2008) 0.87
Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission. Eur J Pharmacol (2008) 0.87
Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther (2014) 0.87
(3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment. Tetrahedron Lett (2008) 0.87
The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther (2011) 0.87
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther (2011) 0.86
The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos (2004) 0.86
Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem (2008) 0.86
Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett (2007) 0.86
5-HT(2C) agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol (2012) 0.84
N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett (2005) 0.83
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem (2009) 0.83
Rearrangement of 3,3-disubstituted indolenines and synthesis of 2,3-substituted indoles. Org Lett (2006) 0.83
The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling. Biochem Biophys Res Commun (2002) 0.83
5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. Int J Neuropsychopharmacol (2009) 0.82
3,4-Dihydropyrimido(1,2-a)indol-10(2H)-ones as potent non-peptidic inhibitors of caspase-3. Bioorg Med Chem (2009) 0.82
Identification of a series of benzoxazoles as potent 5-HT6 ligands. Bioorg Med Chem Lett (2009) 0.82